Diagnosis and management of the metabolic syndrome in obesity
about
Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic targetSibutramine-associated adverse effects: a practical guide for its safe use.Ethnic disparities in metabolic syndrome in malaysia: an analysis by risk factors.Metabolic syndrome among obese Qataris attending primary health care centers in Doha, 2010.The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome.Investigation of relationship of visceral body fat and inflammatory markers with metabolic syndrome and its components among apparently healthy individualsLow levels of serum 25-hydroxyvitamin D and risk of metabolic syndrome in China.Statins: another class of antihypertensive agents?Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?Presence of metabolic syndrome in football linemen.The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus.Pleiotropic effects of thiazolidinediones.Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.Effects of lifestyle interventions and long-term weight loss on lipid outcomes - a systematic review.Dietary modulation of the inflammatory cascade.Effectiveness of community-based exercise intervention programme in obese adults with metabolic syndrome.The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J MiceEfficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.Alcohol consumption, obesity, and psychological distress in farming communities-an Australian study.Soy protein based supplementation supports metabolic effects of resistance training in previously untrained middle aged males.Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.miR-1322 regulates ChREBP expression via binding a 3'-UTR variant (rs1051943)
P2860
Q30370672-745497F1-D863-455F-A084-B5DCF8A8F7E2Q34585304-7AA48D71-BD59-413C-B495-A1A173E1CB63Q35575752-FA6F6C72-87BE-423B-B468-54F01ABBB373Q35890114-3CCD6356-F867-4EB8-A454-278FA3798B38Q36105683-47E2C63D-F6F0-4473-A625-D44D29302FBFQ36182928-3D1061A3-48FA-497A-99EB-895C18C0F8BDQ36183281-8D91DF92-4341-4F75-9884-8904A7BF57F3Q36411099-260804AC-C894-4DD1-86E9-9A1D84A274EEQ36480076-D93F7B65-6E9E-42F3-B3DA-8BD889CC74EFQ36653658-EB5FAA5B-1C2D-43DF-8F2E-46E78AEB7795Q36675450-1AF471F1-E4F4-43DF-9775-4C298B93D352Q36709546-146F2DA5-543C-410F-853A-5DEAC77BCADAQ36971901-E84C9226-77F5-429D-A2D7-686574FC1E07Q37009008-692F5B68-EDD9-4D88-A7F7-E21530AE833AQ37142044-97D0EB8D-35B8-4960-A072-1B9BB05A1A76Q37429913-275C78F5-DFE5-4803-9742-704C399FF8F6Q37849342-D1A09941-5281-4B9E-9A22-D7AF1065A65DQ38169805-88232C43-4EAD-4C1C-B512-B628212AAAA6Q38833451-87DD9F3E-FC33-4A43-9D36-3BFB06ECEF71Q42007043-1B61C517-8A6C-483A-8CE7-AF20B9E1D4C6Q43244897-45F0C3A2-CABD-4156-9375-665122E056D0Q43282311-D1BF53F8-62B6-4820-AAB3-36D0B79DD9FFQ43484384-66BEFF50-6D97-423A-A8E9-B56AD5522579Q44979868-EBBD7D7D-43A2-4ECC-9E57-36987F0F7EBFQ46321376-5588B744-0131-4C86-B31F-50D3C2BB158BQ46389068-C9035623-F37F-43A8-A4E9-CE2E6F44018BQ58799909-FE8D1183-EA58-4AD5-A089-0803CF9FCBF2
P2860
Diagnosis and management of the metabolic syndrome in obesity
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Diagnosis and management of the metabolic syndrome in obesity
@ast
Diagnosis and management of the metabolic syndrome in obesity
@en
Diagnosis and management of the metabolic syndrome in obesity
@nl
type
label
Diagnosis and management of the metabolic syndrome in obesity
@ast
Diagnosis and management of the metabolic syndrome in obesity
@en
Diagnosis and management of the metabolic syndrome in obesity
@nl
prefLabel
Diagnosis and management of the metabolic syndrome in obesity
@ast
Diagnosis and management of the metabolic syndrome in obesity
@en
Diagnosis and management of the metabolic syndrome in obesity
@nl
P2860
P1433
P1476
Diagnosis and management of the metabolic syndrome in obesity
@en
P2093
Mikhailidis DP
P2860
P304
P356
10.1111/J.1467-789X.2005.00221.X
P407
P577
2005-11-01T00:00:00Z